Greetings, and welcome to the Align Technology Incorporated Second Quarter 2015 Financial Results Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Shirley Stacy, Vice President, Corporate and Investor Communications for Align Technology. Thank you. You may begin.

Good afternoon. And thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and David White, CFO. We issued our second quarter 2015 financial results today via MarketWire, which is available on our Web site at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our Web site for approximately 12 months. A telephone replay will be available today by approximately 5:30 PM Eastern Time through 5:30 PM Eastern Time on July 30th. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13612927 followed by pound. International callers should dial 201-612-7415 with the same conference number. As a reminder, the information that the presenters discuss today will include forward-looking statements including statements about Align's future events, product outlook, and the expected financial results for the third quarter 2015. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail on our most recent periodic reports filed the Securities and Exchange Commission. Actual results may vary significantly and Align expressly assumes no obligation to update any such forward-looking statements. We have posted a set of GAAP and non-GAAP historical financial statements including the corresponding reconciliations and our second quarter conference call slides on our Web site under quarterly results. Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

Thanks Shirley. Good afternoon and thanks for joining us. It's a pleasure for me to be here today reporting my first quarter with Align. On our call today, I will provide some financial highlights and then briefly discuss the performance of our two operating segments; Invisalign Clear Aligners and Scanner & Services. Dave will provide more detail on our financials and discuss our outlook for the third quarter. Our second quarter results were good driven by strong Invisalign case volume up 10.5% sequentially and 21% year-over-year with growth across all customer channels and geographies. North America volumes grew 17% year-over-year and our international geographies were up 30% compared to last year. Revenue was near the high-end of our guidance reflecting better than expected volumes offset somewhat by lower ASPs. On a constant currency basis total Q2 revenues were up 14.2% year-over-year and Clear Aligner revenues were up 17.5% year-over-year. In North America, Invisalign volume is driven by growth on both ortho and GP customers. We had another record quarter for North American ortho. Utilization was an increase to 9.5 cases per doctor. North American GP dentist utilization grew slightly to 3 cases per doctor in conjunction with the significant increase in the base of our GP dentist customers. We trained about 1000 doctors during Q2, one of our highest training quarters ever and have more active GPs than ever. I will share a few highlights for North America. We are continuing to implement our sales expansion program and are making progress. Our new approach to customer segmentation and partnering with our customers, practices has been received very positively by our doctors including the addition of our strategic account manager role for a high volume and multi-office customers. The increase in sales reps has increased doctor touch points in both numbers…

Thanks Joe. Let's review our second quarter financial results. Revenue for the second quarter was $209.5 million up 5.8% from the prior quarter and up 8.8% from the corresponding quarter a year ago. On a constant currency basis consolidated world wider revenues were up 1.42% year-over-year. Second quarter Clear Aligner revenue up $200.8 million was up 7.4% sequentially and 11.7% year-over-year. On a constant currency basis Clear Aligners revenues were up 17.5% year-over-year. The sequential revenue growth reflected higher volumes across all of our major geographies and channels offset by lower worldwide ASPs. Q2 ASPs were down sequentially about $35 which is primarily due to higher promotional discounts, higher revenue deferrals as we treat more complex cases and foreign exchange. These costs were only partially mitigated by a price increase we implemented in North America, while that price increase took effect April 1, 2015 it only had a partial impact on the quarter as we work through orders placed at the older price. The largest promotional impact on ASP was related to a new staff Aligner promotion launched in North America in February. This promotion allows active Invisalign trained doctors, who met certain criteria to treat one staff member per year at a reduced price. The promotion is intended to increase practice utilization especially among low volume customers as staff members experienced first hand an Invisalign treatment and have opportunity to share their experience with their patients. We ran a similar program across EMEA last year albeit on a much smaller scale. While it's still very early in terms of this promotion that group participating EMEA doctors has grown 10% faster than non-participating doctors. Our year-over-year revenue growth reflected Invisalign case volume growth across all customer channels partially offset by lower ASPs primarily ready to foreign exchange rates and higher…

Thanks, David. Overall, I'm pleased with the Q2 volume growth and continued strength in our international business. We're making progress and we have a lot of positive momentum. On top of my priorities for the first few months is to get direct feedback from our customers and gain insight into their practices and understand how they can better serve their needs. Still coming up to speed on many things after spending the last several weeks on the road, meeting with customers and employees I believe that I have a good understanding of our business and believe that we have many of the key drivers to further our success. As we scale our business, international is key driver of that growth, the best person to create a unified marketing strategy for the company that leverages opportunities, resources and best practices globally is Raphael. He understands our business and customer dynamics and international markets and will quickly get up to speed in North America. He also has a real passion for improving customer experience as inline with the goals of our company. In summary, we're making positive and forward looking changes for the company. We just reported a solid quarter of growth and we're making measurable progress and improving our customer experience worldwide. We talk about our opportunities because we have a lot of them, simplifying and unifying our sales and marketing across all regions is an important part of seeing and seizing these opportunities while delivering the best products and experiences for our customers and their patients. I'm confident that these changes will help accelerate our progress and continued success. Thank you for your time today. I look forward to meeting our shareholders and analysts over the coming month. With that, I'll now open the call to your questions. Operator?

Thank you. [Operator Instructions] Our first question is from Robert Jones of Goldman Sachs. Your line is open.

Thanks for the questions and welcome Joe. Just a couple of questions on the case growth for the year. It looks like you're seeing, we should expect case growth in about 20% range based on what you've done year-to-date as well as the 3Q guide, it looks like for 4Q you're actually planning on quite a bit of acceleration -- by my math well north of 20%. I'm just curious A, is that the right way to think about how you guys are seeing the back half on a case growth basis and then two, is there anything that gives you greater visibility into 4Q relative to where we are in the year today?

Hi, Robert. First of all, your assessment is correct in a sense we're looking at a pretty big outlook in the second quarter versus the first half. There is positive momentum we talked about in the case growth side you could see that, you could see international is very strong. You could see that the ortho side in the United States has been strong too. As far as the clarity of it, it's based -- on that momentum some historical presence that we have. And also relying on the investments we've made particularly in North American market internationally for increased resources to help you drive that.

That makes sense and then I guess David if I could just follow up on the policy change, anything you can share on what you'd expect the eventual increase to be, I'm just trying to get a sense of how big of a barrier to growth had this been that you guys obviously felt the need to put in place this new policy?

Well, see if I can answer a couple of ways here. When we looked and pulled customers as to their Invisalign experience and how we can improve upon that experience this particular policy change has been the number one item they've asked for. When we look at those customers who are promoters and we compare their growth rates against detractors, we know that whenever we can move a customer who is a detractor or even a passive into a position where they are a promoter, we see significant up tick in volumes as a result. So the policy change is related to that and trying to see if we can capture additional opportunities to prove they're growing the company. And the unfortunate consequence of it is that it requires us to change our deferral and the estimates that we use for deferrals. And so when we look, when we kind of measure our results going forward the year-over-year comparisons are going to be a little tough to make year-over-year until that kind of normalizes out and that will take -- that will take at least one year for the year-over-year comps to normalize out and then probably a couple of years before all those grandfathered cases work them out and when we actually get back to a more normalized operating model.

That's helpful. Thanks.

Thanks Bob.

Our next question is from Steve Beuchaw from Morgan Stanley.

Hi, and thanks for taking the questions everyone. First, my first question is actually on the experience you've had Joe as you've been out talking to customers over the last, I don't know if its six months or so. One of the things that I've heard from customers that I thought you might want to touch on here and not necessarily the initial days but within your first 12 to 18 months, how the company things about using data and how about company things about interacting with the consumer and also the patient. I wonder as you look at how in the company has positioned itself with social media and outreach another company has used information that it is obtained from customers let's say visiting the Web site. What do you thinking about how you are going to use that data more powerfully going forward? And then I have a follow-up.

Steve, I have been impressed since I have been here. Look, my experience has always been to be B2B businesses and obviously, we have both here. I call B2B is moving into the ortho or dentistry side and B2C is what we are doing to consumers. If I look at work on consumers, I see it's very well balanced I think in a sense of using social media using print media and there is a lot of experience here over the years in the sense of what's effective and what's not effective in essence and spend. I'm amazed we could see the statistics I referenced in the opening in the sense of the 27% increase overall in Web business the conversation of Web business into actual unit going on the doc locator. So I feel good about that and I hoping answering your question, secondly, when I see customers, I get two comments all the time. One is, I don't like where I am on doc locator, okay? And that means a lot to me, that means they watch that, it means a whole lot they know generating demand for them. And really the best businesses I have ever been in is when we had customers that looked at the business for demand generation and our customers certainly do that and we do that to our consumer efforts. Secondly, the question that I heard about were the issues on Aligners and having mid-course corrections or whatever. I know it's another thing we want to emphasize in a sense of our customer MPS growth that was really the number one reason and I almost never got out of a doctors office without that being mentioned. So we are trying to improve that customer experience both in consumer standpoint and also B2B standpoint and from what I have seen, I think we are making great strides here over the last year.

Okay. Then my follow-up is related to volume growth. So you guys are taking the volume growth expectations to essentially 20% or better I think that figure previously was somewhat lower say north of 15% but less than 20%. I mean if you have to pick one thing that you have seen incrementally to get you more comfortable with the outlook what might that be and as a corollary to that, can you comment on not necessarily for 2015, but how you think about let's say over the next year the interoperability arrangement that you have with Sirona contributing to the growth story? Thanks so much.

Steve, I will let David answer that I think he can be more specific than I can with this point.

Yes. Steve, I think as we look at – we look at our first quarter performance and we look at our second quarter performance and we measure that against historical patterns here in the company, second quarter and particular we began to see a significant divergence between year-over-year case volume growth and what we have experienced historically when we look at Q2 over Q2 and 2011, 2012, 2013, 2014, we are seeing a gap widening there. And that gap is partly what is giving us confidence that we are going to see a stronger second half. So that's the analytical side of it. And it's clearly more behind that. But, at the highest level that's probably the analytical side of it. But on the other piece of it, which is more qualitative is the fact that we have been doing this for a long time in terms of making investments in our go to market coverage, geographies we are expanding into and so forth. And what we know is that when we invest in directly and go to market, we see a response. And we made the largest step up in investment, I think in the history of the company starting in January and particularly targeted North America. But not discriminating against the international side of it as well. And we are seeing a response to that. And so we are trying to invest into it and keep the growth of the company moving forward and testing just how we continue to grow the markets and invest and what works and what doesn't. We try different promotions. And all these things play together collectively to tell us that we are seeing some traction. On the Sirona question, while we qualified the scanner, their software updates are still going through testing at this point in time and final qualification. It's supposed to be released later this year, I don't know what the specific date is. You might have to find something on their Web site in that regard from them. But, it's moving forward, but when you look at the up lift, I think we talked about this perhaps in another analyst meeting or earnings call, is the fact when you looked at where most of their install base is particularly on the scanner that we are qualifying most of it is overseas, a lot of it is in GP practice, most of our effort internationally is on the ortho side. So what we think is important and why we think it will play to our strategy of continuing to become more relevant the GP practice, we don't see it creating an immediate type of uplift in our business. And we think it's going to be longer journey before we will actually see a blip in the radar on it.

Thanks Steve.

Thanks for all the color guys.

You bet.

Our next question is from Jon Block with Stifel Nicolaus.

Great. Thanks. And good afternoon guys. Joe maybe the first one for you. In EMEA you guys have reaccelerated the growth and pretty handling, you caught markets like Spain, France, Italy, I mean not really the strongest collection of economies in. I know slightly lower penetration over there, but can you talk to what's allowed the reacceleration the 25% to 30% growth maybe if you can address the sustainability of that number one? And number two, is there anything you are doing differently over there? I mean any secret sauce and how you are attacking those markets that arguably could be transferable to the North American market.

Jon good question. I went to Israel in the first couple of weeks I was here to check out the scanner and then up to Amsterdam to really visit some customers and to do some reviews for the team. And I would say, it's funny how Europe is, since individual countries as you know, with different economies and there is different drivers in those industries. And what Ralph and the team have done, they have done a terrific job of being able to figure out in which one of those countries certain formulas actually work for penetration. And even in countries as pressured as Spain which is a great example that drove an incredible amount of penetration in a relatively short amount of time. By actually concentrating resources in a certain ways on those customers to bring them up the speed quickly to make them effective and they can confident in a sense of – we can move teeth and we can move in predictably. And it also creates a – that success creates others wanting to have that success too. In the U.K. on the other hand it hasn't the fairly been an orthodontic push as much as GP. And it's a different formula to go after GP in the U.K also. So Jon just in the time that we have here, I would say we have learned a lot there, Raphael and the team have applied it well. And there is some things honestly we can translate back in North America that can help our records here as we target a different market segments.

Okay, great. Thanks for that. And just a follow up maybe Joe, if you can touch on why now for the additional Aligners at no charge, I mean, what you are hearing from the field, why is the proper time now. And then David to your earlier remarks, I mean obviously people don't want to pay extra, I get it, but what's interesting here is that the same time you are also hitting them with a list in the increase price yet. You say you are increasing the goodwill. So can you talk about those dynamics I guess? What do they want? They want predictability, they are willing to pay a little bit more unless but sort of be assured that they are not going to have additional out of pocket expenses as the case progresses, if you can talk to those dynamics. Thanks guys.

Jon let me start off. Then I will turn it over to David because David has more experience than in this two. I think as you get into the business and you look at this again, the customer calls and stuff I have made just initially, you hear about this additional aligner thing, it's incredible [year to our] [ph] customer base. And it's a lot of reason but it creates uncertainty. And I think we are working with doctors; doctors want more certainty and patients want more certainty. And we feel like this – gives them that kind of control, or feeling what that certainty is. And so I think this is much subjective as it is objective. It's something it's been around a long time. And as I talk to the Align personnel too – many of them say we should have done this years' ago because we know what the issue is and really haven't addressed it. It wasn't till MPS correcting came in. And we could really weigh what that's meant to our business. But, I think it gave us the determination to take the next steps and to make change. David --

I just had one comment to your question about why now? What's – it is a decision that we made but obviously but it isn't one that we made over night or made recently. The actual mechanisms and so forth put into motion on this actually started on it few years ago. And as you can imagine, there is a fair amount of infrastructure in the company, it may sound like a simple change. But, there are a number of nuances associated with it that it required IT development efforts and so forth and other changes that have taken us some while to build, to test and to launch. And so it isn't a decision that's been made over night, it's been working for long time. As it relates to the things that customers are trying to avoid and you mentioned about the price increase and so forth we've had a practice of raising prices modestly every couple of years and typically North America and international have been kind of a little bit out of sync on that because we weren't doing necessarily at the same time. But we felt that we were creating value here for the doctors and their patients that you help substantiate the timing for the price increase as well which is roughly two years since our last price increases. And in terms of things we're trying to avoid you hear -- George comments you hear comments from doctors about they have a patient that has gone off to school -- in the middle of treatment and they get behind and they come back at Thanksgiving and doctors start -- use to start worrying on the policy about that them coming to the end of the runway when they wouldn't -- and then they have to start paying for it and so that put urgencies on their part and so lots of things -- lots of different kinds of personal circumstances could come up in the lives of the patients that our policy didn't particularly respond very well to. And the interesting thing about it is the way the doctors treat their patients they quote the patient a price at the beginning of the treatment and their expectation and then the patient's expectation is that's the price and if it take a -- when you look at wires and brackets if it winds up taking a little bit longer to treat, well, it's still one price and yet in our case it will not have taken a little bit longer to treat they ran into the risk that the cost of the doctor would potentially go up and so this just tends to align our -- as Joe commented in his prepared remarks, it just aligns our business practice to the way our doctors practice with the patient.

And Jon, I had one more thing on the price question too is, we put a lot of technology in the market over the last few years and we think about G4, G5 and now G6, we need a certain amount of payback for that investment also and so there is kind of price increases reporting value in a market place and to emphasize what David said we look at, we're creating value for customers and we feel that we should paid for that also and that's part of the thought process in the price increase.

Perfect. Thank you guys.

Thanks Jon. Next question.

Our next question is from John Kreger from William Blair.

Great, thanks very much. David, may be could you just give us a little bit more numbers on the new strategy around additional alignments -- aligners can you talk about what's the percentage of cases that actually end up ordering it and how many are we talking about and any numbers you could give us there?

Well we don't typically disclose what percentage of cases require refinements. It is varied when you actually kind of dig down into it it's varied by geography. We see more case refinements and so forth internationally what we do domestically. Some of that is driven by the fact that they are treating more complex cases in some of those geographies. And particularly when we get to APAC we see that. And so as we've looked at the incidence you might say of refinement and so forth, our trend has been -- it has been going up over time and it seems to correlate very closely with the degree and complexity of the cases that we're beginning to treat. And so those are the kind of the trend lines and this policy will just simply make it easier for the doctors to do that without creating additional friction for doing what's right for the patients.

Great, thanks. And then as a follow-up Joe, you said I know you've spent a lot of your initial days talking to customers. Beyond their experience with Invisalign what else are they telling, just curious how are they feeling about their practice, is their business getting better or worse given the economy and are you seeing any interesting changes on the competitive front kind of in the lower complexity end of your market.

John, I think its right inline with what I think the statistics you see in dental market right now. Most of the people out there are experiencing growth year-over-year and it looks like it's this year looks very strong, the strongest year they've had. So overall, I mean there is difference between the primary care side and the ortho side, but both of them are reporting, it's really a pretty good business environment now is mostly [indiscernible] is going through. As far as what customers are thinking and talking about also from an Align standpoint and how we interface with them is its -- often when you talk to them I am asking a lot of the detailed questions about customers and how the technology works and what's happened over the years. And you see a lot of enthusiasm for the product. I think not being here three or four years ago, I think there is a lot of skepticism in the marketplace if we can move teeth predictably and then finish case as well. You see many of the doctors I talked to, in fact, all of them, none of them doubt that we can do the things we're doing they get excited about new products like G5 and G6 and the complexity cases that David talked about too. So overall, these have been good conversations outside of some areas of that we need to address like we just have from a customer engagement standpoint and customer satisfaction standpoint, but in that a pretty good marketplace and a lot of people feeling good about Align and our technology.

Great, thank you.

Shawn, next question please.

Our next question is from Jeff Johnson from Robert Baird.

Thank you. Good afternoon guys. Joe, just wanted to ask you on the extra aligners or the additional aligners policy. How much of that is may be going after some competitive accounts as well? I know when we go out and talk to some docs we use may be one or two of your other competitors especially one that you've had some legal issues here, what's recently we hear that's one of those things some docs do like about their policy. Does this -- is this done at all the kind of target that? And then a follow-up there is just you make some personal changes here, you're addressing a primary customer concern is kind of your first two moves that we're seeing publicly anyway anything else I wouldn't expect that you announce a third change here or something on this call, but there are other changes that we should expect to see out of you here in the next three to six months or these kind of the first two big moves that we should expect for the near term?

I'll just answer your last question first, these are the biggest moves I plan to make any time, I can see, I think these are the ones that kind of obvious in the sense that we have to address. From a competition standpoint is, there is not a competitor out there strong enough right now that really force our hand on the additional aligners play. I mean just like the fact is, there is a lot of different dimensions we compete with them both in the United States and internationally that didn't force our hand. Really it's a relationship with our customers, that's what we felt was the right thing to do to address that. It's not saying that five or six years down the road there might have been a different situation, but that wasn't a drive of our decision. As far as competition goes over all, our competition right now is in the lower end of the segment as you know its in the E5, E10 those kinds of easy cases that are out there. It's not forcing us to make any real competitive moves in the sense of addressing that right now in the marketplace but we -- we're very aware of it, we see it overseas as well in the United States, we know over the next couple of years that will increase, but that's not a specific part of our portfolio, it's the easier part of the portfolio, it's not in the G3, G4, G5 and obviously G6 areas, it's smaller movement of teeth. I think the last thing I mentioned is that kind of fell apart or wasn't accentuated a lot in our announcement was the lower arch that we just came out with and we positioned out with the E5 form a pricing stand point too. This is something customers have asked for years if they just -- want to buy aligner for that particular arch. It's very practical in the sense of what they've asked for and we hadn't responded to it and this is something we think will help our customers and will help our future competitiveness also.

Okay, understood. And that was actually going to be my follow-up question on the lower arch, you had mentioned at least in the prepared remarks the single arch so we'll assume that's that lower arch, are you saying that you're going to -- price that kind of the Express 5 level is that what I'm hearing? And then David, I thought the Express 5 promotion was going to end in July, it sounds like may be in your remarks that's going to be extended is that correct in North America that that discounted price that went into effect over the last four or five months?

Yes. Jeff, first of all, when you look at those product line and all we had to reposition the Express 5 pricing to really -- to allow the single arch to have that price point and then we moved up our E5 price and David you give the specifics of what those numbers were.

Okay.

Yes. So Jeff, we haven't -- I don't think we've formally announced it but have we, okay -- I have been told, yes.

[indiscernible] David.

You're right I remember there was an announcement, I know there was -- the promotion that we ran in Q2 actually started in -- towards the end of Q1 and it ran till June 30. Then we had about a three week period before we launch and announce the single arch product and when we announced the single arch product with that we announced a new promotion for E5, one for dual arch and one for single arch. The pricing on the dual arch E5 is higher, the discount is – they are saying differently, the discount is not as large what was in Q2, but yet we're also offering a nice discount on the single arch as well so that when you actually look at those two together we think it will attract the -- we think it will attract adoption for those patients at a nice price point it only needs one arch treated and we think it will still preserve a good demand for those that need dual arch. But the pricing has gone up a little bit from where it was in Q2.

Thank you. Yes, thank you.

Thanks, Jeff. Next question please.

Our next question is from Brandon Couillard from Jefferies.

Thanks. Good afternoon. Joe, you talked a quite a bit about changes in opportunities you're making in the commercial organization. Would be curious to get your view as to the adequacy or efficiency of the R&D budget, in R&D organization and whether you get there -- is room for some further changes or enhancements in that side of the business?

Look, I think from an R&D standpoint there is a lot to do here because there is still a huge amount of penetration we can do especially as we go up the curve in the sense of both on the aligner itself but also the technology we call the digital ecosystem behind that. So look, I like the way it's placed in the sense of the efficiency of it between Russia and United States what we have in Israel on the scanner side. So right now, I feel good about where we are, we put significant number of resources into R&D and technology over the last couple of years, they look like they've been well placed. I talk about going out and seeing customers but [Joe Cole] [ph] who runs our technology organization has spent significant amount of time with -- he and his people here recently too. And really I'm impressed of what we have here. But this is a technology organization this is some -- we have to put money in technology into these products to continue to advance the science. And given the level of penetration and what we've seen as a result of that investment, I think it's a good thing to do.

Excellent, David, the 700 unit iTero orders in the second quarter, were those upgrades or new users and given the new disclosures and the presentation I appreciate that, care to comment on the size of the installed base in North America?

Well, as far as the 700 orders, I don't have the break out here in front of me. But part of that is obviously doctors that are upgrading some of that is doctors that are getting a second scanner for their office. And then there is other doctors that are getting their first scanner. And all of those are great facts for us. We like to see the adoption and Joe mentioned some of the excitement we've seen generally about it and some of the shows we featured it. As far as the installed base, I'm not sure we've upgraded that except -- year end was it Shirley? What was that do you remember?

An analyst meeting, that was all.

About 4,000 I think was the last time we upgraded at the analyst meeting.

Super. Thank you.

Our next question is from Glen Santangelo from Credit Suisse.

Yes. Thanks. And good evening. I just want to talk a little bit about ASPs and margins. I mean I think I understand the commentary this quarter ASPs were impacted by some of the promotional activity may be some higher -- the revenue deferral and FX. But if we kind of look at ASPs in terms of what you're implying next quarter based on the revenue guidance, it looks like ASPs tick down again a fair amount sequentially, is that all attributable to the new deferral arrangement or is there some other promotional activity in Q3 that's kind of worth calling out?

Most of that Glen is related to the – is related to the additional aligners in fact the vast majority of it is. You can compute back into our ASPs probably half of our guidance.

Yes.

Substantially all of this is additional aligners. There is we talked really about a price increase that we implemented – we implemented that effective April 1 in North America. We didn't – we won't see the full effective of that price increase for North America anyway until Q3. We implemented the price increase of €50 in international and that came into effect on July 1. And we will probably going to see a partial impact of that in Q3 is just we work off all cases and so forth that we submitted the old price. And those – and so you got that price uplift there and we got some promotions like we are running on – continue to run on the E5 and so forth and go from there. But not from a quarter-over-quarter standpoint Q2 to Q3 FX is pretty much not in the picture it's really – it's really the change in policy with some plus having the price increase and then some additional promotions.

Okay. That's helpful. And David may if I could expand the conversation into margins, kind of sounds like you are modeling fiscal 2015 without margins down 400 to 500 basis points. But, Joe maybe is a good question for you, on last quarter's call, Tom talked about investment in a new ERP system, he talked about making sleep apnea investment now you kind of have the new sort of deferral arrangement. You got FX kind of playing a role in there. So I'm trying to think about fiscal 2016 margins and I know you don't want to guide on that. But, should I think about or just stay on your margins for the full two years until you sort of work your way or through all the grandfathered cases before we sort of get to a cleaner run rate a couple of years from now. I'm just trying to think about how we should think about the margin progression just kind of knowing the information that you kind of gave us tonight.

I first start off my answer with our goal here to be between 25% and 30% operating margin. This team knows it. I know that. The Board knows it. We want you guys to know that too. This is unusual – this is an unusual year and quarter because just what you mentioned there is ERP, sleep apnea, you have – there is foreign exchange really weighs on year-to-year, it's not going to be quarter-to-quarter. But it's year-to-year right now. And so it's a lot of static in this quarter. And obviously, we prepare to try to make this as clean as possible for you to understand what's going on. There is also behind this whole thing is a significant volume left, we are seeing that now. We feel good about that volume piece and I'm not ready to declare anything for 2016, but you want to see that kind of volume that go into 2016. And we have built the particular operating model around 2016. We are not done with that yet that helps us to go for the goals that we are striving for between 25% and 30%. David, do you want to add anything?

I think Glen your comment about the change it will take probably a couple of years for that to work its way out. So we are going to have that a little bit of a drag on operating margins for that time period. But, once I think that kind of settles out and so forth like Joe said. We expect to be driving the business towards that long-term model. We have hit that long-term model before. We did in 2014. And we are committed to doing it prospectively going forward. And I will just add – I will just add one other thing, as you think about 2016, you realize when we gave our guidance for this year and actually even the comments I made in my remarks today, ERP is a drag on margins of a little over a point right now. And that should fall off mid-year next year. And so there is at least that piece of it, it should get better.

And could you maybe just give us any color on the sleep apnea investment, how big it is and when that should – when we should anniversary that; did that roll off?

Glen, I think the much as I can say about this right now as we are still working that.

Okay.

And determining exactly you know what it means we are still in the beginning phases I would say, we might have been a little bit early and mentioning that to you. And as far as we are working through that in subsequent quarterly reports we will bring up the date.

Okay. Thanks for the details.

Thanks Glenn. And thank you everyone for joining us today. This completes our conference call. If you have any further questions please contact Investor Relations. Have a great day.